Pliant Therapeutics, Inc.
PLRX
$1.07
-$0.01-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.61M | 46.92M | 53.75M | 57.68M | 59.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.61M | 153.77M | 186.02M | 219.86M | 234.91M |
| Operating Income | -116.61M | -153.77M | -186.02M | -219.86M | -234.91M |
| Income Before Tax | -113.22M | -149.34M | -175.50M | -206.96M | -219.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -113.22 | -149.34 | -175.50 | -206.96 | -219.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.22M | -149.34M | -175.50M | -206.96M | -219.52M |
| EBIT | -116.61M | -153.77M | -186.02M | -219.86M | -234.91M |
| EBITDA | -115.10M | -152.08M | -184.23M | -217.98M | -232.85M |
| EPS Basic | -1.84 | -2.43 | -2.87 | -3.39 | -3.61 |
| Normalized Basic EPS | -1.11 | -1.48 | -1.79 | -2.12 | -2.26 |
| EPS Diluted | -1.84 | -2.43 | -2.87 | -3.39 | -3.61 |
| Normalized Diluted EPS | -1.11 | -1.48 | -1.79 | -2.12 | -2.26 |
| Average Basic Shares Outstanding | 246.05M | 245.46M | 244.87M | 244.19M | 243.19M |
| Average Diluted Shares Outstanding | 246.05M | 245.46M | 244.87M | 244.19M | 243.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |